Literature DB >> 559413

Detection, evaluation, and treatment of pituitary microadenomas in patients with galactorrhea and amenorrhea.

R J Chang, W R Keye, J R Young, C B Wilson, R B Jaffe.   

Abstract

Over a period of two and a half years, 34 women with galactorrhea or amenorrhea, all with an abnormal sellar polytomogram, underwent transsphenoidal microsurgical exploration of the sella. Eighteen women and microadenomas (less than or equal to 1 cm. in diameter), seven had macroadenomas (greater than than 1 cm. in diameter), and five had unidentified lesions. Only one women had a normal pituitary gland. Three women had cryosurgery without biopsy. Preoperatively, hyperprolactinemia occurred in 24 of 25 women with adenomas and two of five with nonadenomatous lesions. There were no operative deaths. Significant morbidity occurred in only three patients, none of whom had microadenomas. Postoperatively, menses resumed in 16 of the 17 women with microadenomas and in two of the seven with macroadenomas who presented with amenorrhea. Galactorrhea disappeared in 15 of the 17 women with microadenomas and in four of the seven with macroadenomas who presented with galactorrhea. In five patients with unidentified lesions, a return of menses occurred in two of four with previous amenorrhea, and galactorrhea abated in two of three who presented with lactation. We conclude that sellar polytomography in women with hyperprolactinemia is a useful technique technique for the diagnosis of pituitary adenomas, a lesion which may occur more frequently than previously realized. In addition, transsphenoidal microresection of microadenomas is safe and effective.

Entities:  

Keywords:  Amenorrhea; Biology; Clinical Research; Diseases; Endocrine System; Examinations And Diagnoses; Follicle Stimulating Hormone; Galactorrhea; Genitalia; Genitalia, Female; Gonadotropins; Gonadotropins, Pituitary; Hormones; Laboratory Examinations And Diagnoses; Laboratory Procedures; Lactation; Luteinizing Hormone; Maternal Physiology; Menstruation Disorders; Ovary; Physiology; Pituitary Gland; Pituitary Hormones; Prolactin; Puerperal Disorders; Research Methodology; Urogenital System; Women

Mesh:

Year:  1977        PMID: 559413     DOI: 10.1016/0002-9378(77)90553-1

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  10 in total

Review 1.  Genesis of prolactinomas: studies using estrogen-treated animals.

Authors:  Dipak K Sarkar
Journal:  Front Horm Res       Date:  2006       Impact factor: 2.606

2.  Enlarged adenomectomy for enclosed prolactinomas: a preliminary study of 26 cases.

Authors:  F Grisoli; T Brue; N Graziani; R Costa; J Trouillas; D Begou; P Jaquet
Journal:  Acta Neurochir (Wien)       Date:  1990       Impact factor: 2.216

3.  Prolactinoma in a man following industrial exposure to estrogens.

Authors:  S H Baron; J R Sowers; M Feinberg
Journal:  West J Med       Date:  1983-05

4.  The management of prolactin-secreting pituitary tumors.

Authors:  S R George; G N Burrow
Journal:  J Endocrinol Invest       Date:  1981 Oct-Dec       Impact factor: 4.256

Review 5.  Bromocriptine in the treatment of hypogonadism and male impotence.

Authors:  C M March
Journal:  Drugs       Date:  1979-05       Impact factor: 9.546

6.  Spontaneous regression of pituitary mass in temporal association with pregnancy.

Authors:  H Ikeda; Y Okudaira
Journal:  Neuroradiology       Date:  1987       Impact factor: 2.804

7.  Prolactin-secreting pituitary adenomas.

Authors:  M C Martin; E D Schriock; R B Jaffe
Journal:  West J Med       Date:  1983-11

8.  Effects of bromocriptine on pituitary tumour size.

Authors:  A M McGregor; M F Scanlon; R Hall; K Hall
Journal:  Br Med J       Date:  1979-09-22

9.  Clinical course and outcome of pregnancies in amenorrhoeic women with hyperprolactinaemia and pituitary tumors.

Authors:  T Bergh; S J Nillius; L Wide
Journal:  Br Med J       Date:  1978-04-08

Review 10.  Potential of gene therapy for the treatment of pituitary tumors.

Authors:  R G Goya; D K Sarkar; O A Brown; C B Hereñú
Journal:  Curr Gene Ther       Date:  2004-03       Impact factor: 4.391

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.